Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Kushi Kullar who wrote (7889)	11/30/1998 3:07:00 PM
From: aknahow	Read Replies (2) \| Respond to of 17367

The trial requires a 90 day lookback. Without a recommendation from the DSMB this could not be changed. Read what XOMA itself said and draw your own conclusions. "Neuprex(tm): Meningococcemia What did the DSMB recommend in September 1998? (9/98) As expected, they indicated to us that they saw no safety issues and recommended continuation of the trial. They also requested an additional review shortly before completion of enrollment. Was this additional review part of the original statistical plan for the trial? (9/98) The protocol allows the DSMB to recommend additional reviews (as they did in March when they recommended the September interim analysis). An additional review gives the DSMB the opportunity to take a final look at the results. If the trial design requires any final adjustments, we can make them. If the data are sufficiently positive, we can get a head start with the regulatory authorities."